Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
This hypothalamic obesity is associated with serious metabolic and psychosocial consequences.
The purpose of the study is to compare the change of body weight after 6 months treatment
with a lifestyle intervention + exenatide compare to the one after the same lifestyle
intervention+ placebo in adults patients suffering from a hypothalamic obesity due to
treatment of craniopharyngioma.